Drugs / NYESO-1c259 T cells
NYESO-1c259 T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01343043 | Sep 2012 → Jun 2019 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01567891 | Jul 2013 → Jun 2017 | ovarian cancer | Adaptimmune | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NYESO-1c259 T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01567891 ↗ |
| Known as | GSK 794 | “Gene-modified autologous T cells expressing NY-ESO-1c259, an affinity-enhanced T-cell receptor (TCR) reactive against the NY-ESO-1-specific HLA-A*02-restricted peptide...” PMID 31651363 ↗ Oct 2019 |
| Known as | lete-cel | “Autologous T cells transduced to express a high affinity T-cell receptor specific to NY-ESO-1 (letetresgene autoleucel, lete-cel) show promise in the treatment of metastatic...” PMID 36075914 ↗ Sep 2022 |
| Known as | letetresgene autoleucel | “Autologous T cells transduced to express a high affinity T-cell receptor specific to NY-ESO-1 (letetresgene autoleucel, lete-cel) show promise in the treatment of metastatic...” PMID 36075914 ↗ Sep 2022 |
| Known as | NY-ESO-1 SPEAR T-cells | “Gene-modified autologous T cells expressing NY-ESO-1c259, an affinity-enhanced T-cell receptor (TCR) reactive against the NY-ESO-1-specific HLA-A*02-restricted peptide...” PMID 31651363 ↗ Oct 2019 |
| Action | Deplete | “attack and kill ovarian cancer cells” NCT01567891 ↗ |
| Modality | Cell therapy | “Autologous T cells transduced to express a high affinity T-cell receptor specific to NY-ESO-1” PMID 36075914 ↗ Sep 2022 |
| Route | Intravenous | “administered as a single intravenous (IV) infusion” NCT01567891 ↗ |